ReviewNature reviews. Endocrinology2026
From bench to bedside: the evolving role of iodine in thyroid cancer management.
Review in Nature reviews. Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable four-class machine learning prediction of initial I-131 therapy responses in differentiated thyroid cancer.Annals of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iodine metabolism has a central role in thyroid physiology and thyroid cancer biology, shaping both tumour behaviour and therapeutic strategies. Within the past 20 years, advancements in molecular research and targeted therapies have transformed the understanding of iodine metabolism in thyroid cancer and subsequently changed clinical management. In differentiated thyroid carcinomas, the ability of tumour cells to concentrate iodide provides the biological foundation of radioactive iodine treatment. However, loss of iodide-handling machinery function drives refractoriness in advanced disease, posing a major clinical challenge. Molecular genetics has now been integrated into routine clinical practice and genetically guided strategies to restore iodine uptake in previously non-avid lesions have emerged. This Review synthesizes these breakthroughs across molecular science, pathology, physics and clinical practice. We describe emerging predictive markers of radioiodine-refractory disease and summarize the current state of knowledge on iodide-handling mechanisms, their dysregulation in thyroid tumourigenesis and therapeutic advances made in the past 15 years aimed at redifferentiation. By bridging molecular insights with translational and clinical perspectives, we aim to highlight evolving paradigms that promise to refine patient stratification and improve outcomes in differentiated thyroid carcinoma.
Indexed as
Identifiers
42315928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.